Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein E7 is an oncoprotein encoded by high-risk human papillomaviruses (HPVs), such as HPV16 and HPV18. It disrupts normal cell cycle control by binding to and degrading retinoblastoma protein (pRb), leading to uncontrolled cell proliferation and cancer development. E7 also induces genomic instability, inhibits apoptosis, evades immune responses, and interacts with other viral proteins to promote oncogenesis. It is a target for therapeutic vaccines and small molecule inhibitors.
Therapeutic vaccines generate anti-tumor immunity; small molecule inhibitors targeting E7 function are in development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein E7 (None).